495 related articles for article (PubMed ID: 21967951)
21. Sample size determination in step-up testing procedures for multiple comparisons with a control.
Kwong KS; Cheung SH; Wen MJ
Stat Med; 2010 Nov; 29(26):2743-56. PubMed ID: 20799258
[TBL] [Abstract][Full Text] [Related]
22. Economics in sample size determination for clinical trials.
Torgerson DJ; Ryan M; Ratcliffe J
QJM; 1995 Jul; 88(7):517-21. PubMed ID: 7633878
[TBL] [Abstract][Full Text] [Related]
23. A simple sample size formula for analysis of covariance in randomized clinical trials.
Borm GF; Fransen J; Lemmens WA
J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
[TBL] [Abstract][Full Text] [Related]
24. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
Chen MH; Willan AR
Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
[TBL] [Abstract][Full Text] [Related]
25. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
26. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
27. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
28. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
van der Lee JH; Wesseling J; Tanck MW; Offringa M
J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
[TBL] [Abstract][Full Text] [Related]
29. The effect of bias on the magnitude of clinical outcomes in periodontology: a pilot study.
Fenwick J; Needleman IG; Moles DR
J Clin Periodontol; 2008 Sep; 35(9):775-82. PubMed ID: 18840153
[TBL] [Abstract][Full Text] [Related]
30. The value of information and optimal clinical trial design.
Willan AR; Pinto EM
Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
[TBL] [Abstract][Full Text] [Related]
31. How many do I need? Basic principles of sample size estimation.
Devane D; Begley CM; Clarke M
J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
[TBL] [Abstract][Full Text] [Related]
32. Methodology of superiority vs. equivalence trials and non-inferiority trials.
Christensen E
J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
[TBL] [Abstract][Full Text] [Related]
33. Sample size re-estimation for adaptive sequential design in clinical trials.
Gao P; Ware JH; Mehta C
J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
[TBL] [Abstract][Full Text] [Related]
34. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
35. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
Katz J; Finnerup NB; Dworkin RH
Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
[TBL] [Abstract][Full Text] [Related]
36. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
Ogungbenro K; Aarons L
J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
[TBL] [Abstract][Full Text] [Related]
37. Adaptive design clinical trials and trial logistics models in CNS drug development.
Wang SJ; Hung HM; O'Neill R
Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
[TBL] [Abstract][Full Text] [Related]
38. Information-based monitoring of clinical trials.
Tsiatis AA
Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
[TBL] [Abstract][Full Text] [Related]
39. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
[TBL] [Abstract][Full Text] [Related]
40. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials.
Pope JE; Bellamy N
Clin Invest Med; 1995 Feb; 18(1):1-10. PubMed ID: 7768060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
